Progenics up after Canada approves Relistor

Progenics (NASDAQ:PGNX) gained $1.14 (17%) to $7.67 on Tuesday after Health Canada approved subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with advanced ...